Sugi Predict

Sugi Predict / Compounds / SCHEMBL951309

SCHEMBL951309

SCHEMBL951309

CC(C)(C)OC(=O)N1CCC(C(=O)OCc2ccccc2)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STS P08842 1/20 0.56
▸ SMN1; SMN2 Q16637 3/20 0.56
▸ NPC1 O15118 2/20 0.56
▸ RAB9A P51151 2/20 0.56
▸ HTT P42858 1/20 0.55
▸ CYP2C19 P33261 1/20 0.54
▸ JAK2 O60674 1/20 0.53
▸ JAK1 P23458 1/20 0.53
▸ GPR119 Q8TDV5 2/20 0.51
▸ USP30 Q70CQ3 4/20 0.49
▸ KDM4E B2RXH2 1/20 0.48
▸ PKM P14618 1/20 0.48
▸ CTSL P07711 1/20 0.48
▸ HPGD P15428 1/20 0.47
▸ GABRA1 P14867 1/20 0.47
▸ GABRG2 P18507 1/20 0.47
▸ GABRB3 P28472 1/20 0.47
▸ GABRA3 P34903 1/20 0.47
▸ GABRA2 P47869 1/20 0.47
▸ GABRB2 P47870 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15626861 1.00 STS (0.56) STSSMN1; SMN2NPC1RAB9AHTT
SCHEMBL9038044 1.00 STS (0.56) STSSMN1; SMN2NPC1RAB9AHTT
SCHEMBL14348074 0.96 STS (0.53) STSSMN1; SMN2NPC1RAB9AHTT
SCHEMBL14348055 0.93 ALDH1A1 (0.55) STSSMN1; SMN2NPC1RAB9AHTT
SCHEMBL2070692 0.93 ALDH1A1 (0.55) STSSMN1; SMN2NPC1RAB9AHTT
SCHEMBL2374261 0.93 SMN1; SMN2 (0.62) STSSMN1; SMN2NPC1RAB9AHTT
SCHEMBL15378237 0.91 SMN1; SMN2 (0.63) STSSMN1; SMN2NPC1RAB9AHTT
SCHEMBL26390347 0.91 SMN1; SMN2 (0.63) STSSMN1; SMN2NPC1RAB9AHTT
SCHEMBL15378236 0.91 SMN1; SMN2 (0.63) STSSMN1; SMN2NPC1RAB9AHTT
SCHEMBL17874004 0.90 HPGD (0.54) STSSMN1; SMN2NPC1RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637440-B2 Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof LG CHEM, LTD. (KR) 2026-05-26 — — US disclosed
CN-114901653-B Novel amide derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof 株式会社LG化学 2024-11-22 — — CN disclosed
US-20230101389-A1 NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF LG CHEM, LTD. (KR) 2023-03-30 — — US disclosed
US-20230023559-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2023-01-26 — — US disclosed
CN-115611933-A Process for preparing arginase inhibitors and synthetic intermediates thereof 因赛特公司 2023-01-17 — — CN disclosed
EP-4074701-A1 NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF Lg Chem, Ltd. (KR) 2022-10-19 — — EP disclosed
EP-4041229-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. Shaw Research, LLC (US) 2022-08-17 — — EP disclosed
CN-114901653-A Novel amide derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof 株式会社LG化学 2022-08-12 — — CN disclosed
WO-2021071806-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2021-04-15 — — WO disclosed
US-9765016-B2 S1P modulating agents BIOGEN MA INC. (US) 2017-09-19 — — US disclosed
EP-2705030-B1 PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC (US) 2016-07-27 — — EP disclosed
US-20150361029-A1 S1P MODULATING AGENTS BIOGEN MA INC. 2015-12-17 — — US disclosed
WO-2012154676-A9 PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC. (US) 2014-03-27 — — WO disclosed
US-8426420-B2 Heterocyclic pyrazole-carboxamidesas P2Y12 antagonists SANOFI (FR) 2013-04-23 — — US disclosed
WO-2012154676-A1 PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2012-11-15 — — WO disclosed
EP-2238128-B1 HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS SANOFI SA (FR) 2012-08-22 — — EP disclosed
US-20110021537-A1 HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2011-01-27 — — US disclosed
EP-2238128-A2 HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS Sanofi-Aventis (FR) 2010-10-13 — — EP disclosed
WO-2009080226-A2 HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS SANOFIS-AVENTIS (FR) 2009-07-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021537-A1 HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS P2RY1, P2RY12, P2RY11 STS 1289/4885SMN1; SMN2 4214/4885NPC1 4195/4885
US-20150361029-A1 S1P MODULATING AGENTS S1PR3, S1PR5, S1PR1 STS 2442/4885SMN1; SMN2 4375/4885NPC1 3013/4885
US-20230101389-A1 NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF DGAT2, DGAT1, MOGAT2 STS 1279/4885SMN1; SMN2 4708/4885NPC1 429/4885
US-20230023559-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNJ2, KCNA3, KCNH3 STS 706/4885SMN1; SMN2 1712/4885NPC1 1807/4885
US-12637440-B2 Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof DGAT2, DGAT1, DLAT STS 402/4885SMN1; SMN2 4700/4885NPC1 278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.